10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility post ...

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company ...

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

The case is 10x Genomics Inc v. Curio Bioscience Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-01375. For 10x: Matthew Powers, Paul Ehrlich, Stefani Smith and Robert Gerrity ...

10x Genomics, a life sciences company, says it will construct up to three buildings on a site a short distance from Stoneridge Shopping Center in Pleasanton.

Life-sciences technology startup 10x Genomics Inc. said its initial public offering was priced above the high end of the expected range, giving it a valuation topping $3.6 billion.